SAFE AND EFFECTIVE USE OF PLERIXAFOR PLUS G-CSF IN DYALISIS-DEPENDENT RENAL FAILURE

Valeria Pinto (1) , Andrea Castelli (1) , Gianluca Gaidano (2) , Annarita Conconi (1)

1 AOU Maggiore della Carità
2 Amedeo Avogadro University of Eastern Piedmont

Plerixafor, a selective antagonist of the CXC chemokine receptor 4, is approved for hematopoietic stem cell mobilization in lymphoma and multiple myeloma patients who previously failed mobilization with the sole G-CSF. Reduced doses of the drug can be safely administered in cases of moderate renal impairment. However, the use of plerixafor in dialysis-dependent patients has not been reported. We report a case of safe administration of plerixafor in a patient with dyalisis-dependent renal failure complicating multiple myeloma and subsequent successful myeloablative chemotherapy with stem cell rescue. In our experience plerixafor might be safe and effective in combination with G-CSF in end-stage renal failure. The toxicity profile and optimal dose of the drug in this clinical setting should be assessed in large series of patients.

Mots clés: Medicine

Valeria Pinto, Andrea Castelli, Gianluca Gaidano, Annarita Conconi. SAFE AND EFFECTIVE USE OF PLERIXAFOR PLUS G-CSF IN DYALISIS-DEPENDENT RENAL FAILURE. American Journal of Hematology, 2010, ⟨10.1002/ajh.21712⟩. ⟨hal-00552319⟩